Evercore ISI analyst Gavin Clark-Gartner removed Viridian Therapeutics from the firm’s tactical outperform list following recent data from their IGF-1R antibody for thyroid eye disease. The analyst thinks this this data derisks their subcutaneous program and improves the long-term outlook for the company and made no change to the firm’s Outperform rating or $62 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics price target raised to $46 from $40 at B. Riley
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- ‘The Likelihood of Recession in the Next 6 Months Is Low’: Credit Suisse Suggests 2 Stocks to Buy
- Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
